Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.
Triple Negative Metastatic Breast Cancer|Advanced Ovarian Cancer|Carboplatin|Paclitaxel
DRUG: KU-0059436 (AZD2281)(PARP inhibitor)|DRUG: Carboplatin|DRUG: KU-0059436 (AZD2281)(PARP inhibitor)|DRUG: Paclitaxel|DRUG: KU-0059436 (AZD2281)(PARP inhibitor)|DRUG: Paclitaxel + Carboplatin
To establish the maximum tolerated dose (MTD) of KU 0059436 in combination with Paclitaxel/Carboplatin, assessed at each visit
To identify the dose limiting toxicity of the combination therapy, assessed at each visit
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.